Patents Examined by Jasemine C. Chambers
  • Patent number: 5759782
    Abstract: The cDNA and amino acid sequences for a cellular apoptosis susceptibility (CAS) protein are used to detect expression and amplification of the CAS gene in normal and cancer cells. An antisense CAS gene sequence introduced into living cells inhibits CAS protein activity and thus prevents or inhibits apoptosis in the cells.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: June 2, 1998
    Assignee: The United States of America
    Inventors: Ira Pastan, Ulrich Brinkmann
  • Patent number: 5759765
    Abstract: Immortalized cell lines derived from normal adult human liver are described which express phenotypic characteristics of normal adult liver epithelial cells. The invention further provides methods of using the immortalized cells to evaluate the cytotoxicity or carcinogenicity of a compound.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: June 2, 1998
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Curtis C. Harris, Katharine H. Cole, John F. Lechner, Roger Reddel
  • Patent number: 5759535
    Abstract: The present invention is directed to a method for the treatment of neoplastic disease comprising administering to a mammal having a tumor a cellular immunogen comprising an allogeneic population of cells expressing S one or more cytoldnes and tumor associated antigens encoded by autologous genomic tumor DNA.
    Type: Grant
    Filed: May 13, 1994
    Date of Patent: June 2, 1998
    Assignee: Research Corporation Technologies, Inc.
    Inventor: Edward P. Cohen
  • Patent number: 5753490
    Abstract: A recombinant human immunodeficiency virus (rHIV) and recombinant mammalian cell-line (packaging systems) and a method for treating infection of cells by human immuneodeficiency virus HIV. rHIV, such as rHIV-1, comprises of a gene construction which includes a foreign gene. The expression of this gene is activated in human cells in the presence of wild-type HIV. This gene product can cause cell death in the presence of an appropriate drug, e.g. Acyclovir. This gene product is typically a viral thymidine kinase. rHIV is so constructed that it is unable to replicate by itself due to the absence of a regulatory gene that is necessary for its replication, such as tat or rev or both. The recombinant mammalian cell-line packaging system comprises in its genome a recombinant gene construction which typically includes a functional regulatory gene from HIV which is missing from rHIV, such as the tat or rev genes or both.
    Type: Grant
    Filed: November 28, 1995
    Date of Patent: May 19, 1998
    Assignee: Clinical Technologies, Inc.
    Inventors: Syed Zaki Salahuddin, Nickolas Chelyapov
  • Patent number: 5753268
    Abstract: Anti-cholesterolemic eggs are disclosed, said eggs being obtained from animals hyperimmunized against at least one anti-cholesterolemic antigen. A vaccine producing said anti-cholesterblemic egg is disclosed, said vaccine comprising at least one anti-cholesterolemic antigen. Further, a dietary supplement for humans and other animals which does not elevate serum lipid, concentrations is disclosed, said supplement comprising the anti-cholesterolemic eggs or fractions thereof. A method for treating vascular disorders in humans and other animals is also disclosed which comprises administering to said subjects said anti-cholesterolemic eggs for a time and in amounts sufficient to produce anti-arteriosclerotic effects, anti-aging vascular effects, and/or serum lipid-lowering effects.
    Type: Grant
    Filed: February 15, 1991
    Date of Patent: May 19, 1998
    Assignee: DCV Biologics, L.P.
    Inventors: Ralph J. Stolle, Lee R. Beck
  • Patent number: 5753505
    Abstract: The present invention provides an isolated cellular composition comprising greater than about 90% mammalian, non tumor-derived, neuronal progenitor cells which express a neuron-specific marker and which can give rise to progeny which can differentiate into neuronal cells. Also provided are methods of treating neuronal disorders utilizing this cellular composition.
    Type: Grant
    Filed: July 6, 1995
    Date of Patent: May 19, 1998
    Assignee: Emory University
    Inventor: Marla B. Luskin
  • Patent number: 5753499
    Abstract: The invention concerns an improvement in the art of inserting and expressing foreign gene into eukaryotic cells. The invention particularly concerns methods and compositions whereby viral vectors can be used to insert and express foreign genes into specifically cells having particular differentiation antigens. A method of determining which differentiation antigens can be used is taught. The invention encompasses complexes of viral particles and adapters that cause the binding and internalization of the vector particles such that a gene of interest in the particle is expressed.
    Type: Grant
    Filed: December 23, 1994
    Date of Patent: May 19, 1998
    Assignee: New York University
    Inventors: Daniel Meruelo, Koichi Ono, Christine Pampeno
  • Patent number: 5750825
    Abstract: There is provided a mouse lacking the function of the endotheline-1 gene by insertion of another gene into the endotheline-1 gene.The mouse is useful for elucidation of the pathological physiology and causes of and development of therapies for cardiovascular diseases such as hypertension, arteriosclerosis and ischemic heart disease.
    Type: Grant
    Filed: April 24, 1995
    Date of Patent: May 12, 1998
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Yoshio Yazaki, Hiroki Kurihara, Yukiko Kurihara, Hiroshi Suzuki, Tatsuhiko Kodama
  • Patent number: 5747336
    Abstract: Clones of human genes for a plurality of different muscarinic acetylcholine receptors and stable cell lines homogeneously expressing a specific subtype of the receptors have been prepared. A method for screening muscarinic drugs has been described.
    Type: Grant
    Filed: August 29, 1994
    Date of Patent: May 5, 1998
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Tom I. Bonner, Mark Robert Brann, Noel J. Buckley
  • Patent number: 5744122
    Abstract: The presence of clonal macrophages in pre-cancerous and cancerous tissue represents an early stage of the disease in which clonal expansion of macrophages occurs due to HIV integration or other genetic mutation. Clonally expanded macrophages induce proliferation of surrounding tissue leading to cancerous tumor growth. The invention provides methods and kits for diagnosis of HIV- and non-HIV-associated clonal expansion of macrophages in pre-cancerous and cancerous tissue. The invention also provides methods for the treatment of cancers induced by clonal macrophage expansion and proliferation of surrounding tissue.
    Type: Grant
    Filed: February 15, 1996
    Date of Patent: April 28, 1998
    Assignee: University of California, San Franciso
    Inventors: Michael S. McGrath, Brian Herndier, Bruce Shiramizu
  • Patent number: 5744347
    Abstract: The present invention is directed to mammalian yolk sac stem cells. In particular, it relates to the characterization, culturing, long-term expansion and uses of yolk sac stem cells for in vivo reconstitution and therapy. Yolk sac stem cells isolated from the early embryonic yolk sac prior to blood island formation exhibit a homogeneous morphology and a primitive cell surface phenotype without the expression of mature leukocyte markers and major histocompatibility complex-encoded antigens. The cells can be cultured and expanded long-term with minimal differentiation, and without alteration of their pluripotency. However, such cells can be induced to express various blood cell markers upon stimulation with specific cytokines. In addition, the cells also express certain endothelial cell markers and growth characteristics. Such yolk sac cells may be particularly effective in the reconstitution of a lymphohematopoietic system, as they are capable of forming both endothelial cells and blood cells.
    Type: Grant
    Filed: April 6, 1994
    Date of Patent: April 28, 1998
    Assignee: Ohio University Edison Biotechnology Institute
    Inventors: Thomas E. Wagner, Michael R. Antczak
  • Patent number: 5744159
    Abstract: A plasmid entrapping multilamellar liposome for introducing a gene into cells, which liposome has constitutive lipids of N-(.alpha.-trimethylammonioacetyl)-didodecyl-D-glutamate chloride (TMAG); dioctanoylphosphatidyl choline (DOPC) or didecanoylphosphatidyl choline (DDPC); and dioleoylphosphatidyl ethanolamine (DOPE) or dilauroylphosphatidyl ethanolamine (DLPE) and in a molar ratio of 1:2-3:2-1 in case of lipid combination of TMAG, DOPC and DOPE, or 1:2:2 in case of lipid combination of TMAG, DDPC or DOPC and DLPE.
    Type: Grant
    Filed: March 14, 1997
    Date of Patent: April 28, 1998
    Assignee: Institute of Applied Biochemistry Gifu-ken
    Inventors: Kunio Yagi, Mariko Kitoh, Nobuko Ohishi
  • Patent number: 5741672
    Abstract: The structural genes and their regulatory DNA sequences of an alcohol oxidase (MOX) and a dihydroxyacetone synthase (DHAS) of Hansenula polymorpha have been isolated and the nucleotide sequences determined. The invention relates to the use of the MOX gene, as well as the use of the regulatory DNA sequences of MOX and/or DAS in combination with the MOX gene, optionally after modification thereof, or other oxidase genes, or other genes, to produce engineered microorganisms, 0in particular yeasts. Said engineered microorganisms can produce oxidases or other enzymes in yields that allow industrial application on a large scale. Moreover, said engineered microorganisms can produce oxidases having improved properties with respect to their application in oxidation reactions and/or in bleaching and detergent products.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: April 21, 1998
    Assignee: Unilever Patent Holdings B.V.
    Inventors: Adrianus M. Ledeboer, Jan Maat, Cornelis T. Verrips, Christiaan Visser, Zbigniew A. Janowicz, Cornelis P. Hollenberg
  • Patent number: 5741665
    Abstract: The al-3 and related promoters can be used to provide light-regulated recombinant production of heterologous proteins in filamentous fungi. Expression systems utilizing these promoters can be placed in vectors which also optionally contain selectable marker means.
    Type: Grant
    Filed: May 10, 1994
    Date of Patent: April 21, 1998
    Assignee: University of Hawaii
    Inventors: Elie K. Kato, W. Dorsey Stuart
  • Patent number: 5736388
    Abstract: Lamboid bacteriophage capable of specifically interacting with and delivering nucleic acid molecules to eukaryotic cells are disclosed. Such bacteriophage-derived gene transfer systems target one or more specific receptors on eukaryotic cells, for instance by incorporating mutant tail fiber proteins or by incorporating known ligands for specific eukaryotic receptors into lambda phage. Also disclosed are methods for identifying and producing modified bacteriophage tail fiber polypeptides capable of specifically interacting with eukaryotic transmembrane proteins. Methods of treating diseases using such gene transfer systems are also disclosed.
    Type: Grant
    Filed: December 30, 1994
    Date of Patent: April 7, 1998
    Inventors: Sunil Chada, Thomas W. Dubensky, Jr.
  • Patent number: 5736524
    Abstract: Genes encoding Mycobacterium tuberculosis (M.tb) proteins were cloned into eukaryotic expression vectors to express the encoded proteins in mammalian muscle cells in vivo. Animals were immunized by injection of these DNA constructs, termed polynucleotide vaccines or PNV, into their muscles. Immune antisera was produced against M.tb antigens. Specific T-cell responses were detected in spleen cells of vaccinated mice and the profile of cytokine secretion in response to antigen 85 was indicative of a T.sub.h 1 type of helper T-cell response (i.e., high IL-2 and IFN-.gamma.). Protective efficacy of an M.tb DNA vaccine was demonstrated in mice after challenge with M. bovis BCG, as measured by a reduction in mycobacterial multiplication in the spleens and lungs of M.tb DNA-vaccinated mice compared to control DNA-vaccinated mice or primary infection in naive mice.
    Type: Grant
    Filed: November 14, 1994
    Date of Patent: April 7, 1998
    Assignees: Merck & Co.,. Inc., N. V. Innogenetics S.A.
    Inventors: Jean Content, Kris Huygen, Margaret A. Liu, Donna Montgomery, Jeffrey Ulmer
  • Patent number: 5736387
    Abstract: The invention provides retroviral vectors which can be used for directing gene delivery to a specific sub-population of mammalian cells. The vectors comprise chimeric targeting proteins which specifically alter the host range of the vector. The chimeric targeting proteins contain a ligand moiety which is capable of binding to receptors present on target cells, and an uptake moiety which is capable of promoting entry of the vector into the target cell. The ligand moiety is derived from a cytokine that acts upon the target cells of interest, and the uptake moiety is derived from a retroviral envelope protein.
    Type: Grant
    Filed: June 1, 1994
    Date of Patent: April 7, 1998
    Assignee: Targeted Genetics Corporation
    Inventors: Ralph W. Paul, Robert Overell
  • Patent number: 5733541
    Abstract: Processes, compositions and uses of hematopoietic cells are disclosed. Hematopoietic cells are cells which can differentiate into mature blood cells when co-cultured with osteoblasts. Specifically, a process for propagating and maintaining the immature morphology of a hematopoietic cell by co-culturing with osteoblasts is disclosed. The osteoblasts provide cytokines and/or a microenvironment which propagates and maintains the immature morphology of a hematopoietic cell. Hematopoietic cells are useful in the treatment of certain blood related disorders and are useful for treatment of patients in need of hematopoietic cells.
    Type: Grant
    Filed: April 21, 1995
    Date of Patent: March 31, 1998
    Assignee: The Regent of the University of Michigan
    Inventors: Russell S. Taichman, Stephen G. Emerson
  • Patent number: 5731416
    Abstract: The present invention relates to the development of a new class of oligonucleotide surrogates capable of sequence specific binding to simple stranded DNA and RNA as well as to double stranded DNA targets. More specifically, structures (Ser/Thr?CH.sub.2 B!-AA).sub.n represent the repeating structural units for a number of the nucleic acid surrogates of the present invention. Once synthesized (in suitably protected form), the monobasic units are linked together via peptide bonds to produce the required oligomeric structures having defined nucleobase sequences. These nucleic acid surrogates may then be utilized for use as antisense/antigene probes and/or drug carriers.
    Type: Grant
    Filed: May 14, 1996
    Date of Patent: March 24, 1998
    Assignee: Case Western Reserve University
    Inventor: Philip P. Garner
  • Patent number: 5726059
    Abstract: Translation characteristics of an mRNA molecule in a cell can be altered by providing a prosthetic RNA molecule that includes a regulatory sequence element and a sequence element complementary to a portion of the mRNA molecule. Alteration can affect the translation rate, the mRNA stability, or the localization of the mRNA molecule.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: March 10, 1998
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Marvin P. Wickens, Michael D. Sheets